hypertensie High blood pressure Hypertension
Conditions
Interventions
RFSD or addition of spironolacton in a maximal dose of 50 mg per day. Per
treatment arm 47 evaluable patients are needed. Follow-up duration after
intervention is 6 months.
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age between 18 and 75 yrs Treatment-reistant hypertension Willingness to give written informed consent
Exclusion criteria
Exclusion criteria: Secondary forms of hypertension Renal arteries not accessible to intervention Suboptimal dosing of anthypertensive medication White coat hypertension Pregnancy Renal insufficiency (GFR
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in 24-hour ambulatory blood pressure decrease between the RFSD and spironolactone group. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Proportion of patients per intervention group with normalization of their 24-hour ambulatory blood pressure - Proportion of patients per intervention group with a decrease in 24-hour ambulatory blood pressure of >= 10 mmHg systolic and >= 5 mmHg diastolic. - Cost effective of RFSD - Difference in scores of quality of llife between RFSD and spironolactone group - Predictive value of clonidine-suppressiontest for the blood pressure response to RFSD | — |
Countries
Netherlands
Outcome results
None listed